Advanced Search

 

Study ID Status Title Patient Level Data
407 Completed Pharmacokinetics and metabolism of Wellbutrin (bupropion hydrochloride) sustained-release in healthy smokers versus non-smokers.
408DP-02 Completed A Multi-Centre Randomized, Double-Blind, Parallel-Group, Comparison of Salmeterol Xinafoate Inhalation Rotadisk Versus Tulobuterol Tape in Subjects with Persistent Adult Asthma Treated with Inhaled Corticosteroid.
408DP-03 Completed A Multi-Centre, Randomized, Double-Blind, Parallel-Group, Comparison of Salmeterol Xinafoate Inhalation Rotadisk Versus Placebo in Subjects with Chronic Obstructive Pulmonary Disease Treated with Current Medications.
40UK Completed Effect of multiple doses of bupropion on antipyrine disposition in healthy volunteers.
40UKA Completed The disposition of bupropion and its basic metabolites in young and elderly healthy volunteers.
424323/007 Completed A study to assess the effect of repeat dosing of a New Chemical Entity (NCE) on the steady-state pharmacokinetics and pharmacodynamics of digoxin in healthy volunteers.
430C/83/6 Completed The single dose kinetics in man of 120mg of BW430C, a potential anticonvulsant.
444563/001 Completed A phase I, double-blind, randomized, placebo-controlled study of the safety and reactogenicity of a single oral dose of the SmithKline Beecham Biologicals’ live attenuated human rotavirus (HRV) vaccine in healthy adults aged 18 to 45 years
444563/002 Completed A phase I, double-blind, randomized, placebo-controlled study of the safety and reactogenicity of GSK Biologicals’ live attenuated human rotavirus vaccine at 2 different virus concentrations in healthy seropositive children between 1 and 3 years of age, when given as a single oral administration Study Listed on ClinicalStudyDataRequest.com
444563/003 Completed A phase II, double-blind, randomized, placebo-controlled, dose-escalating, stepwise study to assess safety, reactogenicity and immunogenicity of GlaxoSmithKline Biologicals’ live attenuated human rotavirus (HRV) vaccine in healthy infants previously uninfected with human rotavirus. Study Listed on ClinicalStudyDataRequest.com
444563/004 Completed A study to assess the efficacy, immunogenicity and safety of two doses of oral live attenuated human rotavirus (HRV) vaccine (Rotarix) in healthy infants. Study Listed on ClinicalStudyDataRequest.com
444563/004 Annex Completed A phase IIb, double-blind, randomized, placebo-controlled study to assess the efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals oral live attenuated human rotavirus (HRV) vaccine in healthy infants approximately 2 months of age and previously uninfected with HRV
444563/005 Completed Phase II, double-blind, randomized, placebo-controlled study of 2 doses of GSK Biologicals’ live attenuated human rotavirus vaccine at different virus concentrations (10 5.2 and 10 6.4 ffu) in healthy infants following a 0, 2 month schedule and previously uninfected with human rotavirus. Study Listed on ClinicalStudyDataRequest.com
444563/006 Completed To assess the efficacy, immuno & safety of 2 doses of GSK HRV vaccine at different virus concentrations in healthy infants aged 2 months & previously uninfected with HRV, concurrently given with DTPw-HBV, Hib. Study Listed on ClinicalStudyDataRequest.com
444563/006 Annex Completed A study to assess efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biological’s live attenuated human rotavirus vaccine at different virus concentrations in healthy infants and previously uninfected with HRV, when administered concurrently with DTPw-HBV and Hib vaccines
444563/007 Completed Study to assess efficacy, immunogenicity, reactogenicity and safety of two doses of GSK Biologicals' oral live attenuated human rotavirus vaccine at different viral concentrations in healthy infants previously uninfected with human rotavirus and approximately 3 months of age. Study Listed on ClinicalStudyDataRequest.com
444563/013 Completed A phase II, randomized, double-blind, placebo-controlled study of safety, reactogenicity and immunogenicity of 2 or 3 doses of GSK Biologicals’ oral live attenuated human rotavirus vaccine at 10E6.5 CCID50 viral concentration in healthy infants (approximately 5-10 weeks old) in the Republic of South Africa Study Listed on ClinicalStudyDataRequest.com
444563/014 Completed Reactogenicity & immunogenicity study of two doses of GSK Biologicals’ oral live attenuated HRV vaccine co-administered with either OPV or IPV in healthy infants (approximately 5-10 weeks old) in South Africa Study Listed on ClinicalStudyDataRequest.com
444563/020 Completed Phase II, double-blind randomised, placebo controlled clinical dose-range study to assess immunogenicity and reactogenicity of an investigational vaccination regimen, and to assess immunogenicity of OPV orally co-administered to healthy infants at 2, 4 and 6 months of age Study Listed on ClinicalStudyDataRequest.com
444563/021 Completed Phase II, double-blind, randomized, placebo-controlled clinical study to assess immunogenicity and reactogenicity of doses of a modified vaccine formulation versus GSK Biologicals’ live attenuated human rotavirus vaccine when orally administered to healthy infants at 2, 4 and 6 months of age Study Listed on ClinicalStudyDataRequest.com
444563/022 Completed A phase II, double-blind, randomized, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of three doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) vaccine Study Listed on ClinicalStudyDataRequest.com
444563/023 Completed A placebo-controlled, multi-country & multi-center study to assess the efficacy, safety & immunogenicity of 2 doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants Study Listed on ClinicalStudyDataRequest.com
444563/023(2) Completed A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-centre study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants.
444563/023(3) Completed A phase III, double-blind, randomized, placebo-controlled, multi-country and multi-center study to assess the efficacy, safety and immunogenicity of two doses of GSK Biologicals’ oral live attenuated human rotavirus (HRV) vaccine in healthy infants.
444563/024 Completed A multi-country & multi-center study to assess the efficacy, immunogenicity & safety of two doses of GSK Biologicals' oral live attenuated HRV vaccine given concomitantly with routine EPI vaccinations including OPV in healthy infants Study Listed on ClinicalStudyDataRequest.com

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.